Search
Advanced search

Company search

Company/VAT no/Free text Country/City/Municipality

TURNOVER (x1000 NOK)

NET PROFIT (x1000 NOK)

EMPLOYEES

Octapharma Nordic AB

Closing information (x1000 NOK)

Closing information 2024/12 (consolidated) 2023/12 (consolidated) 2022/12 (consolidated)
Turnover 40,955,908 Less Arrow 36,709,878 Less Arrow 30,024,840
Financial expenses 103,854 Less Arrow 20,503 More Arrow 35,380
Earnings before taxes 6,386,536 Less Arrow 4,948,539 More Arrow 5,385,096
EBITDA 8,103,106 Less Arrow 6,530,541 More Arrow 6,854,481
Total assets 58,482,778 Less Arrow 49,826,927 Less Arrow 44,560,567
Current assets 44,465,440 Less Arrow 36,851,003 Less Arrow 31,870,450
Current liabilities 5,644,376 Less Arrow 4,671,953 Less Arrow 4,199,969
Equity capital 50,296,050 Less Arrow 43,058,973 Less Arrow 38,096,082
- share capital 1,418 Less Arrow 1,349 Less Arrow 1,263
Employees (average) 10,501 More Arrow 10,587 Less Arrow 9,734

Financial ratios

Fiscal year 2024/12 (consolidated) 2023/12 (consolidated) 2022/12 (consolidated)
Solvency 86.0% More Arrow 86.4% Less Arrow 85.5%
Turnover per employee 3,900 Less Arrow 3,467 Less Arrow 3,085
Profit as a percentage of turnover 15.6% Less Arrow 13.5% More Arrow 17.9%
Return on assets (ROA) 11.1% Less Arrow 10.0% More Arrow 12.2%
Current ratio 787.8% More Arrow 788.8% Less Arrow 758.8%
Return on equity (ROE) 12.7% Less Arrow 11.5% More Arrow 14.1%
Change turnover 3,584,117 More Arrow 4,554,567 More Arrow 5,688,247
Change turnover % 10% More Arrow 14% More Arrow 23%
Chg. No. of employees -86 More Arrow 853 More Arrow 1,398
Chg. No. of employees % -1% More Arrow 9% More Arrow 17%

Total value of public sale

Fiscal year 2024/12 (consolidated) 2023/12 (consolidated) 2022/12 (consolidated)
Total value of public sale 0 Equal arrow 0 Equal arrow 0

Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank

The closing information is gathered directly from the companies or from Creditsafe.